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CAD         Æ  Coronary artery disease 
CVD Æ Cardiovascular disease 
CRP Æ C – reactive protein 
EDRF Æ Endothelial derived relaxing factor 
ELISA Æ Enzyme linked immunosorbant assay 
HDL Æ High density lipoprotein 
IHD Æ Ischemic heart disease 
LDL Æ Low density lipoprotein 
TGL Æ      Triglycerides  
MCP-1 Æ Monocyte chemoattractant protein – 1 
PDGF Æ Platelet derived growth factor 
UAE Æ Urine albumin excretion 
VCAM-1 Æ Vascular cell adhesion molecule-1 
TNF Æ Tumour necrosis factor 
IL-1 Æ Interleukin – 1 
RIA Æ Radio immunoassay 
PGI2 Æ Prostaglandin I2 
n Æ      Frequency 
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INTRODUCTION
IHD which has an estimated prevalence of 6–9 % in general 
population in India may become the leading cause of mortality and 
morbidity in India by year 2025. Since the pioneering work of 
Framingham study, many prospective and clinical studies have identified 
series of independent risk factors for ischemic heart disease among which 
age, male gender, a positive family history of premature atherosclerotic 
disease, cigarette smoking, diabetes mellitus, hypertension, dyslipidemia, 
obesity, physical inactivity are traditional risk factors. 
The interest in improving cardiovascular risk assessment, resulting 
from a better understanding of the pathogenesis of atherosclerosis and 
identification of new targets for anti-atherosclerotic drug therapy has 
stimulated the search for novel risk factors. One such novel risk factor is 
microalbuminuria which has emerged as an independent and robust risk 
factor.
Microalbuminuria is a marker of widespread vascular damage in 
diabetic as well as non-diabetic patients. However more and more 
evidence is accumulating that microalbuminuria is an important 
cardiovascular risk factor even in general population. Its early detection 
helps in preventing the progression of cardiac decompensation. 
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Aggressive treatment of microalbuminuria is associated with improved 
renal and cardiac functions. 
The present study is being conducted to determine the prevalence 
of microalbuminuria in non-diabetic and non-hypertensive ischemic heart 
disease patients and its association with other known cardiovascular risk 
factors.
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AIM OF STUDY 
1. To find out the Prevalence of microalbuminuria in non-diabetic 
and non-hypertensive patients with Coronary heart disease .
2. To find out the association between microalbuminuria and 
smoking.
3. To find out the association between microalbuminuria and 
hyperlipidemia.
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REVIEW OF LITERATURE
IHD
Ischemia refers to a lack of oxygen due to inadequate perfusion of 
the myocardium, which causes an imbalance between oxygen supply and 
demand. The most common cause of myocardial ischemia is obstructive 
atherosclerotic disease of epicardial coronary arteries.
Pathogenesis of Atherosclerosis:
Marchand introduced the term “Atherosclerosis” describing the 
association of fatty degeneration and vessel stiffening1. This process 
affects medium and large sized arteries and is characterized by patchy 
intramural thickening of the sub-intima that encroaches on arterial lumen. 
Atherosclerotic plaque has three principal components. The first is 
cells including smooth muscle cells, macrophage and other leukocytes. 
The second component is extracellular matrix including collagen, elastic 
fibers and proteoglycan. The third component is intracellular and 
extracellular lipid. These components occur in varying proportion and 
configuration in different lesions 
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Initiation of Atherosclerosis:
Endothelial Injury:
The luminal surface of a normal artery is covered with a 
monolayer of endothelial cells attached to sub endothelial matrix. The 
endothelial cells also provide the artery with nonthrombogenic surface. 
Injured endothelial cells appear morphologically different from normal 
endothelial cells; unlike normal cells, they are typically not aligned in the 
direction of blood flow and they have fewer intracellular attachments 
resulting in increased permeability2. Injured endothelial cells are also 
more thrombogenic than the normal endothelial cells because of their 
diminished production of PGI2 and EDRF-NO3. Injured endothelial cell 
promote vascular smooth muscle cell migration and proliferation by 
releasing less EDRF-NO and by secreting PDRF and endothelial-14.
Finally injured endothelial cell promote the recruitment of macrophage 
by secreting Monocyte Chemoattractant Protein-1(MCP-1) and by 
expressing cell surface receptors or selectins to which monocyte can 
bind5, 6, 7.
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Role of Inflammation:
Following endothelial dysfunction, endothelial cells express 
VCAM-1 which binds monocyte and T-lymphocyte. The monocyte 
migrates between extracellular matrix to localize in intima and 
transforms into macrophage and become lipid laden foam cells. 
Macrophage produces IL-1, TNF and MCP-1, which further cause 
migration of leukocytes into arterial wall. The lipoproteins that enter into 
the intima of arteries associate with glycosaminoglycans of arterial 
extracellular matrix, an interaction that slows egress of these lipid-rich 
particles from the intima. The lipoprotein undergoes oxidative 
modification to form oxidized LDL which are preferentially endocytosed 
by macrophage through macrophage scavenger receptors. Thus the 
monocyte attachment to endothelium, migration into the intima and 
maturation to form lipid-laden macrophage represents key steps in 
formation of the fatty streak.
FIBROTIC LESION FORMATION:
Fatty streak are converted to fibrotic lesion by forming fibrotic cap 
composed of smooth muscle cells. The PDGF causes migration of 
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smooth muscle cells from media into the intima. TGF-BETA potentially 
stimulates interstitial collagen production by smooth muscle cell thus 
leading to formation of fibro fatty lesion.  
ADVANCED LESION FORMATION: 
The final stage in the development of an atherosclerotic lesion is 
the conversion of fibrotic lesion into advanced lesion, a lesion in which a 
thrombus has formed subsequent to either plaque ulceration or 
intraplaque hemorrhage.4, 8,9,10 The relative paucity of smooth muscles in 
advanced atheroma may result from the predominance of cytostatic 
mediators such as TGF-ALPHA or INF GAMMA and from smooth 
muscle cell apoptosis. 
EPIDEMIOLOGY AND PREVENTION OF 
ATHEROSCLEROSIS:
Atherosclerosis is a multifactorial disease where age of onset and 
progression are strongly influenced by inborn and acquired risk factors. 
Since the pioneering work of the Framingham study, many prospective 
population and clinical studies have identified a series of independent 
risk factors for myocardial infarction, stroke and PVD, among which the 
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pre-existence of atherosclerotic vascular disease, age, male gender, a 
positive family history of premature atherosclerotic disease, smoking, 
diabetes mellitus, hypertriglyceridemia, hypercholesterolemia,  
hypertension  and low HDL cholesterol are considered as 
classical risk factors
In a given individual, the presence of a single risk factor has a low 
positive predictive value. In contrast, the presence of several moderately 
expressed risk factors can produce a significant increase in 
cardiovascular risk.
Therefore at present the most advanced strategy for coronary risk 
assessment is to combine the information of several risk factors in 
algorithm or scores. Current international guidelines base their 
recommendations for the indication of hypolipidemic drug treatment in 
clinically asymptomatic patients (primary prevention) on the estimation 
of global risk. 
Thousands of cross-sectional case control studies have identified 
hundreds of clinical, biochemical or genetic markers that showed 
statistically significant association with coronary heart disease, stroke, 
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PVD. Most of the associations were either not reproducible in other 
studies or not independent of clinical risk factors. However some of these 
emerging risk factors, turned out to be robust and independent. Currently 
there is an intense discussion whether they should be introduced into 
routine risk assessment. This specially concerns lipoprotein (a), CRP, 
fibrinogen, homocysteine and microalbuminuria 
MICROALBUMINURIA:
A consensus conference in 1995 defined microalbuminuria in 
individual with diabetes as a abnormal urinary excretion rate of albumin 
between the range 20 – 200 µg/min or 30 – 299 mg/day.11 This is still the 
definition used today and is applicable to all people regardless of 
associated pathological condition. 
Prevalence of microalbuminuria:
Type 1 diabetes– 4 - 40%, Type 2 diabetes – 30 - 40%, 
hypertension – 7- 40%, Non – diabetic – 5 - 7%.
Epidemiologic and experimental date shows that microalbuminuria 
is associated with an increased risk for all cause and cardiovascular 
mortality, cardiac abnormality, cardiovascular disease and periodically 
PVD.
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In Heart outcome prevention evaluation (HOPE) study, UAE 
predicted mortality in patients who were at cardiovascular risk (55 years 
of age with CVD (or) DM and at least one other cardiovascular risk 
factor).12 All cause mortality was 9.4% among patient without   
microalbuminuria versus 18.2% among those with microalbuminuria 
[Relative Risk(RR)]2.09% ; 95% confidence interval] . A linear 
relationship was also observed between microalbuminuria level and 
cardiovascular events, extending below the traditional microalbuminuria 
threshold. 
The presence of microalbuminuria also seems to predict all cause 
mortality in the personal population. This was initially shown in 
Prevention of renal and vascular end stage disease (PREVEND STUDY), 
in which inhabitant of Gramingam, The Netherland, who were aged 28 - 
75 years were sent a questionnaire and a vial to collect an early-morning 
urine sample for measurement of  UAE. A total of 40,548 participants, 
who were followed for 26 years were included in an analysis of   
mortality  by baseline UAE. A clear positive relationship was observed 
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between UAE and all cause cardiovascular and non cardiovascular 
mortality. 
In the Steno hypothesis put forward by Deckert et al, albumin 
leakage into the urine is a reflection of widespread vascular damage. This 
hypothesis links impaired vascular endothelial function with vascular 
leakage of albumin. The kidney thus would become a window to the 
vasculature.
In the non-diabetic American Indians of the strong heart study, the 
prevalence of coronary heart disease, peripheral vascular disease and 
stroke was associated with microalbuminuria (ACR between 30 and 
300mg/g) independent of age, diabetes, systolic blood pressure, 
cholesterol and fibrinogen.51, 52
Stronger evidence for microalbuminuria as an independent risk 
marker was produced by Damsgaard et al.53who showed prospectively a 
threefold higher death rate in normoglycemic individuals where 
albuminuria was equal to or above the median (>7.52 microgram/min). 
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Table 1: Clinical studies reporting the risk associated with positive 
microalbuminuria results 
No Study MicroalbuminuriaDefinition Population
Risk associated with 
positive
microalbuminuria
results
(95% CI) 
(A) Prospective studies
1 Prospective 
studies
HOPE17
ACR >=2 mg/mmol 
in a 
First morning spot 
urine 
sample 
Subjects at high 
cardiovascular
risk
>=55 yr with 
CVD or 
with  diabetes 
+>=1
CVD risk factor; 
n = 9043) 
All-cause mortality: 
RR
2.09 (1.84 to 2.38) 
2 PREVEND18 UAE 20 to 200 
mg/L in 
an early morning 
spot 
urine sample 
Residents of 
Groningen,
The Netherlands, 
28 to75 yr 
(n = 40,548) 
Cardiovascular death: 
RR 1.29(1.18 -1.40) 
Non cardiovascular 
death:
RR 1.12 (1.04 to 1.21) 
3 PREVEND19 UAE 30 to 300 mg 
in a 
24-h urine Sample 
Residents of 
Groningen, the 
Netherlands, 28 
to 75yr  
(n = 7330) 
All-cause mortality: 
HR 3.3 (1.5 to 7.1) for 
patients with ST-T 
segment changes with 
microalbuminuria 
versus 0.9 (0.4 to 1.9) 
for ST-T segment 
changes alone 
Cardiovascular death: 
HR 10.4 (2.5 to 43.6) 
for patients with ST-T 
segment changes with 
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microalbuminuria 
versus2.7(0.6 to 12.3) 
for  ST-Tsegment 
changes alone 
4 Hoorn Study20 ACR >= mg/mmol 
in a 
first morning spot 
urine 
sample 
Population-
based:
White
individuals, 50 
to 75 yr (n = 
631)
Cardiovascular death: 
RR3.22 (1.28 to 8.06) 
All cause mortality: 
RR 1.70(0.86 to 3.34) 
All-cause mortality in 
patients with 
hypertension: RR 2.87 
(1.22 to 6.33) 
5 HUNT21 ACR >=76 
mg/mmol 
(60th percentile) in 
a first morning 
urine sample 
Non- diabetic, 
non-hypertensive
residents of
Nordrondelag
Norway,
>=20 yr(n=2089)
All-cause mortality: 
RR 2.3 (1.0 to 5.4) 
6 EPIC-Norfolk22 ACR 2.5 to 25 
mg/mmol 
in a random spot 
urine 
sample 
Residents of 
Norfolk, 
UK, 40 to 79 yr 
(n =20,911) 
All-cause mortality: 
HR1.48 (1.20 to 
1.79)Cardiovascular 
death: HR 2.03 (1.55to 
2.67) Fatal stroke: HR 
1.58 (1.10 to 
3.0)Coronary heart 
disease death: HR 2.01 
(1.40 to 2.90 
7 EPIC-Norfolk23 ACR 2.5 to 25 
mg/mmol 
in a random spot 
urine 
sample 
Residents of 
Norfolk, UK, 40 
to 79 
yrs(n=23,630)
Stroke: HR 1.49 (1.13 
to 2.14) 
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8 Danish24
MONICA
ACR >0.65 
mg/mmol 
(>90thpercentile) in 
a
first-morning spot 
urine 
Population-
based:
Individuals 
without IHD, 
renal failure, 
UTI, diabetes 
Ischemic Heart 
Disease: 
RR 2.3 (1.3 to 3.9) 
9 Shibata Study25 Positive albumin 
dipstick
test
Residents of 
Shibata,
Japan, >40 yr (n 
=2651)
Stroke: RR in men 2.5 
(1.1 to 5.7) 
10 Portland26
Study
UAE 20 to 200 
mg/L in a 
first morning spot 
urine 
sample) 
Older residents 
of
Portland,
Oregon, with 
previous stroke 
or
transient
ischemic 
attack (n =121) 
Recurrent stroke: HR 
4.9(1.4 to 17.6) 
11 Slowik et al.27  UAE 30 to 300 mg 
in a 
24-h urine Sample 
Patients admitted
within 24 h of
first ischemic 
stroke
(n = 60)
Mortality: OR 6.0 (1.3 
to27.7)
 (B) Cross-sectional studies
12 Cross-
sectional28
studies
Zander et al.
UAE 20 to 200 
mg/L in 
an early morning 
spot 
urine sample 
Patients with type 2 
Diabetes.(n = 1060) 
PAD: OR 2.1 (1.4 to 
3.2)
13 PREVEND29 UAE 30 to 300 
mg in a 
24-h urine sample 
Non-diabetic
residents
of Groningen, the 
Netherlands, 28 to 
75yr
Electrocardiographic
abnormalities: Infarct 
patterns: OR 1.61 (1.12 
to 2.32) 
Major ischemia: OR 
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Table 2 : List of the available cross-sectional (C) and prospective (P) 
studies reporting data about non-diabetic microalbuminuria and/or 
urinary albumin excretion as a covariate and/or predictor of 
cardiovascular events 
No Author/ref. Date N Design End-point Population
1 Yudkin42 1988 187 C/P Major, minor ECG 
changes,
history of MI and 
angina peripheral 
vascular disease 
Diabetic, glucose-
intolerant and 
non-diabetic
subjects
2 Haffner43   1990 316 C Self-reported MI Non-diabetic 
subjects
3 Damsgaard44 1990 216 P Total mortality Non-diabetic subject
4 Winocour45 1992 447 C ECG abnormalities Diabetic and non-
diabetic subjects 
5 Damsgaard46  1992 216 P Total abnormality Non-diabetic 
subjects
6 Damsgaard47  1993 216 P Total mortality Non-diabetic 
subjects
7 Gould MI48 1994 959 C M I, angina, 
peripheral
Non-diabetic
subjects
(n = 7579) 1.43 (1.08 to 1.91) 
Minor ischemia: OR 
1.32 (1.03 to 1.68) 
14 PREVEND30 UAE 30 to 300 
mg in a 
24-h urine sample 
Non-diabetic
residents
of Groningen, the 
Netherlands, 28 to 75 
yr(n = 6669) 
PAD : OR 0.98(0.68 to 
1.41) in multivariate 
analysis
16

vascular disease  
8 Howard49 1995 4549 C Definite MI and 
ischemic 
heart disease 
Diabetic and non-
diabetic
American Indians 
9 Kuusisto50 1995 1069 P Fatal and non-fatal 
coronary
heart disease 
Non-diabetic
subjects
Pathophysiology of microalbuminuria: 
The intimate relationship between low level albumin excretion and 
vascular permeability makes urinary albumin excretion highly sensitive 
to the presence of any inflammatory process, including cardiovascular 
disease. The kidney is ideally placed to amplify any small changes in 
systemic vascular permeability. The glomeruli receive 25% of cardiac 
output. Of the 70kg of albumin that pass through the kidneys every 
24hours, less than 0.01 % reaches the glomerular ultra filtrate (i.e., less 
than 7g/24hrs ) and hence enter the renal tubules.32,33
Almost all the filtered albumin is reabsorbed by the proximal 
tubule through a high affinity, low capacity endocytotic mechanism, 34
with only 10-30mg/24hrs appearing in urine. Assuming that 7g of 
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albumin is filtered every 24hrs; a 1% increase in systemic vascular 
permeability in response to an inflammatory stimulus would results in an 
additional 70mg of albumin passing into the filtrate. Since tubular 
mechanisms for albumin reabsorption are near saturation, urinary 
albumin excretion would increase from a maximum of 30 to approx 
100mg/24hr. 
Glomerular permeability to albumin is dependent on endothelial 
charge selectivity as well as size selectivity. The negative charge 
conferred on glomerular membrane by its constituent glycoprotein plays 
a role in restricting the permeability of anionic proteins. Loss of 
glomerular charge selectivity has been found in both diabetic and non-
diabetic population with microalbuminuria.35, 36. Similarly, alteration in 
the fraction of plasma filtered by glomeruli due to changes in blood 
pressure and intra glomerular pressure regulation may also result in 
relatively large changes in urinary albumin excretion. 
Microalbuminuria may be a marker of generalized vascular disease 
with arterial endothelial dysfunction being involved in the pathogenesis 
of atherothrombotic vascular disease. 
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In an individual with microalbuminuria who does not have 
diabetes, both endothelial dysfunction and alteration in ECM contribute 
to increase in vascular permeability and ultimately promote the 
atherosclerotic process. Defective endothelial permeability permits lipid 
influx into the vessel wall causing  atherosclerotic changes.37,38,39 An 
impairment of normal endothelial antithrombotic and vasodilatory 
properties is a main factor in atherogenesis.40 Endothelial dysfunction 
seems to play a key role in non-diabetic glomerulosclerosis and 
atherosclerosis. Microalbuminuria is also associated with biochemical 
indices of endothelial dysfunction such as increased VWF and increased 
platelet adhesiveness. In both non-diabetic and diabetic patients, it was 
observed that participants with microalbuminuria had higher plasma level 
of VWF antigen than patient with normal albumin excretion.  
Microalbuminuria and cardiovascular disease may be linked not by 
a common risk factor but rather by a common pathophysiological 
process. One is that, dysfunction of the vascular endothelium causes both 
microalbuminuria and cardiovascular disease.54,55 Generalized endothelial 
dysfunction now is considered a transducer of atherogenic  risk factor 
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and is thought to play an important role in both the initiation and 
progression of atherosclerosis. Abnormalities in the endothelial 
glycocalyx may contribute to microalbuminuria but also have been 
implicated in pathogenesis of atherosclerosis, thus providing a potential 
direct link between microalbuminuria and cardiovascular disease.
Microalbuminuria is a marker of widespread vascular damage in 
diabetic as well as non-diabetic patient. Microalbuminuria is also 
associated with presence of other well recognized risk factor for CAD. Its 
early detection helps in preventing the progression of cardiac 
decompensation. Aggressive treatment of microalbuminuria is also 
associated with improved renal and cardiac functions.
An unfavorable pattern of lipid abnormality already exists at the 
stage of microalbuminuria when renal function is still normal. The 
abnormality consists of elevated total cholesterol and VLDL and reduced 
HDL.
Another interesting theory is that some individuals are born with 
varying degree of vascular function within a physiologic range and 
therefore excrete a variable amount of microalbuminuria. This inherent 
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variability of the vascular state as determined by urine microalbumin 
excretion may be associated with susceptibility to subsequent organ 
damage. This could also explain why microalbuminuria is a predictor of 
not only CVD but also new-onset hypertension and diabetes. If this 
proves to be the case, then it may be desirable to identify these 
individuals to consider early interventional strategies to provide primary 
prevention.
Microalbuminuria is associated with increased cardiovascular 
disease as most commonly microalbuminuria reflects pathophysiological 
process predisposing to atherothrombosis. Atherothrombosis is low grade 
inflammatory disease of vessel wall characterized by endothelial 
dysfunction and increased transendothelial passage of leucocytes. This 
feature could be the pathogenic factor linking microalbuminuria to 
cardiovascular disease.56
Screening for Microalbuminuria:
Urinary albumin concentration can be quantified by a number of 
antibody based assay. These include Radioimmunoassay, Laser 
neplometry, Immunoturbimetry and ELISA. 
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Although the gold standard test for microalbuminuria is the RIA, 
other tests are generally sensitive enough for clinical practices. 
Immunoturbidimetric assay of microalbuminuria is depending on 
the turbidity of a solution when albumin in sample of urine reacts with a 
spectrophotometer and the absorbency is proportional to the albumin 
concentration. Recently an assay called HPLC was used to measure 
unreactive intact albumin that is not recognized by immunologic 
methods. However, the clinical significance of this method is not fully 
understood. Whichever method used, the same assay should be used 
when comparing the albuminuria results over time for a patient. The 
choice of assay used is largely determined by issues of accuracy, cost & 
convenience.
One of the most extensively investigated methods to screen for 
microalbuminuria is the immunometric dipstick micraltest, microbumin 
test. Because these tests are semi-quantitative, a true co-efficient of 
variation cannot be determined. In general these albumin reagent strip 
test are more sensitive than standard dipsticks, but they also have a 
relatively high rate of false-positive results. For the diagnosis of 
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microalbuminuria, a 24 hour urine collection is the gold standard. 
Because of the effort involved, it is not the method of choice for 
screening. The second best is a timed overnight urine collection. Again 
because this requires collection of urine over a given time period, this 
may be acceptable for screening specific groups such as patients with 
diabetes or hypertension but less feasible for population screening. The 
next best is a first morning void urine sample. This has advantages over a 
spot-urine sample because it is always performed at the same time of the 
day and it is least influenced by hydration status and physical activity of 
the patient, reducing the variability that is caused by these factors. 
The albumin-to-creatinine ratio (ACR) in random or timed urine 
collection may be more quantitative than a simple dipstick screening 
procedure but has a number of limitations. For eg:  
-Obtaining ACR on morning first void sample may underestimate 
24hour protein excretion because of reduction in proteinuria that occurs 
normally at night.                    
-The fact that urinary creatinine must be measured in addition to 
albumin introduces another source of error.
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-Urine creatinine concentration is extremely variable, so very 
different ratios can be obtained in individuals with similar protein 
excretion rates. 
-Moreover creatinine excretion in the urine depends not only on 
gender but also on age and race.57, 58
This may explain why urinary albumin concentration from a spot 
sample performs equally well for definition of microalbuminuria as 
albumin-to-creatinine ratio.59
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Table  3 :Classification of abnormal urinary albumin excretion:
24 Urine 
Albumin
(mg/24 h)
Overnight
Urine
Albumin
(microg/min)
Spot Urine
Albumin
(mg/L)
Albumin/Creatinine
Ratio
G*
mmol/g mg/g
Normal
<15 <10 <10 M <1.25 <10 
F  <1.75 <15 
High normal   
15 to <30 10 to <20 10  
To<20
M 1.25  
To <2.5 
10
To<20
F 1.75
To<3.5
15
to<30    
Microalbuminuria   
30 to<300 20 to <200 20  
To<200
M 2.5  
to 25
20
to<200
F  3.5  
to 35 
30
to<300
Macroalbuminuria  
>300 >200 >200 M >25  >200 
F  >35 >300 
G* - Gender 
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MATERIAL AND METHODS
The study was carried out in the Department of General Medicine, 
Tirunelveli medical college hospital, Tirunelveli.
Study Design:
Randomized hospital based study.
Study subjects:
50 non diabetic and non hypertensive CAD patients were selected 
from those admitted in General Medicine wards and Cardiology 
Department during the period March 2010 to November 2010
Inclusion Criteria
1. The diagnosis of coronary heart disease was based on 12 lead ECG, 
cardiac enzyme estimation, echocardiography and rose questionnaire.
2. Normal values of Total cholesterol <200 mg/dl, HDL >40mg/dl 
[Male] >50mg/dl [Female], TGL 150mg/dl, LDL <130 has been 
taken as the cut-off value for this study.
Exclusion Criteria
1. Hypertension defined as JNC VII and patients who were taking      
anti hypertensive drugs.
2. Diabetes mellitus defined as per ADA criteria
3. Patients with urinary tract infection, congestive cardiac failure, 
seizures and fever
4. Urine showing - macroalbuminuria.
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Methods of collection of DATA
This was hospital based study involving 50 patients.
Data collection was by clinical history, examination and 
investigations  such as blood investigations- fasting blood sugar, blood 
urea, serum creatinine, serum electrolytes, fasting lipid profile, urine 
albumin and deposits, chest X ray PA view, ECG, Echo are done and 
reports were analyzed thoroughly. 
Microalbuminuria was detected by immunoturbidimetric method 
in early morning first voided urine.
The reference range of normal microalbuminuria is 0 – 20 mg/l
Early morning first voided urine after discarding initial 10 – 20 ml 
urine was collected using sterile plastic container and investigation was 
done within 2 hours of collection of urine.
Statistical Analysis:
The DATA is presented as Mean ± 2SD. The limits of significance 
were calculated using SPSS version 13 software.
Statistical Software:
Microsoft Word and Microsoft Excel were used to generate graphs, 
tables, etc. 
27

       OBSERVATIONS AND RESULTS 
RESULTS:
Fifty patients fulfilling the criteria for the study were included. The 
study was done over a period of nine months. Data was collected as per 
the proforma attached
1. Sex distribution:
In the present study, out of 50 patients, 35 were males and 15 were 
females.
Table 4: Sex distribution in study subjects 
M: F ratio = 2.33: 1 in this study 
Sex  No. of patients Percentage 
Male  35 70% 
Female  15 30% 
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2. Age and sex wise distribution of the study subjects: 
Table 5: Age and sex wise distribution of the study subjects  
Age Groups 
(Years)
Sex Total 
Male Female
n % n % n   % 
20-29 1 2.9 - - 1 2 
30-39 2 5.7 - - 2 4 
40-49 7 20 - - 7 14 
50-59 15 42.9 6 40.0 21 42 
60-69 7 20 7 46.7 14 28 
70-79 3 8.5 2 13.3 5 10 
Total 35 100 15 100 50 100 
Mean± SD 53.8± 11.6 60.5± 6.7 55.8± 10.7
Significance t=2.099    and    P <0.05
The mean age of the study population was 55.8 ± 10.7 with the 
range of 26 – 75years. The median age was 57years. The mean age for 
males was 53.8±11.6years and the same of females was       
60.5 ± 6.7years.The difference of mean was statistically significant         
(P <0.05).This interpretation reveals that males were affected by CAD 
earlier than females 
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3. Family history of ischemic heart diseases:
Table 6: Family history of ischemic heart disease in study subjects 
    Family history of IHD was present in 38%of the study subjects. 
Family history
of IHD 
Sex Total  
Male
(n=35)
Female
(n=15)
No  20 11 31 
Yes  15 4 19 
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4. Sex wise classification of study subjects according to the smoking 
habit
Table 7: Sex wise classification of study subjects according to the 
smoking habit  
History
Sex
TotalMale (n=35) Female (n=15) 
      n     %      n     %   n  % 
Smokers      33    94.3      Nil     Nil    33  66 
Non smokers       2    5.7      15    100    17  34 
Total      35    100      15    100    50  100 
Among  the males 94.3% were smokers and 5.7% were non 
smokers.100% of women were non smokers. 
5.Sex wise classification of study subjects according to family history 
Table 8: Sex wise classification of study subjects according to family 
history
History                  Male                 Female         Total 
     n         %       n      %      n      % 
Yes     15    42.8       4     26.6     19      38 
No     20    57.1      11     73.3     31      62 
Total     35    100      15     100     50     100 
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6.Physiological ,biochemical profile & microalbuminuria of the study 
subjects
Table 9:Physiological, biochemical profile and microalbuminuria of 
the study subjects 
Variables    Mean SD  Median   Mode     
Systolic BP 115.6 9.5 120 110 
Diatolic BP 74.8 6.5 80 80 
Fasting blood sugar 100.0 8.6 100 100 
Total CHO 178.6 26.8 178.5 175 
TGL 144.5 51.1 137 110 
HDL 42.6 3.8 42.5 40 
LDL 123 24.8 120 120 
Microalbuminuria 35.9 22.2 30 30 
The above table shows description of the physiological 
measures.The Mean±SD, Median, Mode of each variables were 
represented. In this study, the major dyslipidemia was increased TGL, 
increased LDL & decreased HDL  
33

7.Comparison of  smoking habit with the age of study subjects 
Table  10 :Comparison of smoking habit with the age of study 
subjects
Category Yes No Difference 
of   mean t
Degree
of
freedom
Pn Mean 
 age 
SD n Mean 
age
SD
Smoking  
habit 33 52.9 11.3 17 61.5 6.8 8.6 2.891 48 <0.01 
     The above table shows the mean age of smokers who were affected by 
the disease was 52.9±11.3years and the same of the non-smokers was 
61.5±6.8 years.The difference between the mean was statistically highly 
significant (P< 0.01). 
8.Abnormal Lipid Parameters: 
Table 11 :Abnormal lipid parameters 
Lipid parameters Male (n=35) Female(n=15) Total (n=50)
n % n % n % 
Total CHO (200mg%) 8 22.9 4 26.7 12 24 
TGL (>150mg%) 11 31.4 7 46.7 18 36 
HDL (M<40mg% F<50mg%) 2 5.7 13 86.7 15 30 
LDL (130mg%) 12 35.3 6 40 18 36 
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9. Distribution of microalbuminuria in various age groups: 
Table 12: Distribution of microalbuminuria in various age groups 
Age in years 
Microalbuminuria
(mg/L)
<20 20
n % n % 
26-35 0 - 4 100 
36-45 2 40 3 60 
46-55 1 8.33 11 91.67 
56-65 7 33.3 14 66.67 
66-75 2 25 6 75 
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10. Level of microalbuminuria (mg/L) 
Table 13: Levels of microalbuminuria (mg/L) 
Microalbuminuria
(mg/L)
Male
(n=35)
Female
(n=15)
Total
(n=50)
n % n % n % 
<20 8 22.9 4 26.7 12 24% 
20-40 18 51.4 7 46.7 25 50% 
>40 9 25.7 4 26.7 13 26% 
There were 25 males (71.4%) and 12 females (80%) with abnormal 
microalbuminuria level in the present study.  
This shows that patients with microalbuminuria are having a 
higher risk of developing ischemic heart disease.  
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11.Prevalence of microalbuminuria in non-diabetic non-hypertensive 
CAD patients: 
Table13: Prevalence of microalbuminuria in non-diabetic
 non-hypertensive CAD patients 
Microalbuminuria
      CAD  Patients     Significance 
n         % 
P < 0.001 Normal(<20mg/l) 12 24 
Abnormal(20mg/l) 38 76 
The above table shows the prevalence of microalbuminuria among 
CAD patients as 76% and the same of the normal population is 15%.The 
difference between the two prevalence rates was statistically significant 
(P<0.001). 
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12. Association between microalbuminuria and smoking habit in the 
study subjects: 
Table 14: Association between microalbuminuria and smoking habit 
in the study subjects 
 Smoking   Microalbuminuria Chi- 
square
Degree of
Freedom 
Significance
Normal 
(<20mg/l) 
Abnormal
(20 mg/l) 
Total
Yes 8 25 33 0.003 1 P>0.05 
No 4 13 17 
Total 12 38 50 
There are 33 patients with history of smoking, out of which        
25 had microalbuminuria and in 17 nonsmokers, 13 had 
microalbuminuria. The observation from the above table shows that there 
was no association between microalbuminuria and smoking (P>0.05).  
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13. Association between microalbuminuria and familyhistory of CAD
Table 14: Association between microalbuminuria with family history 
of CAD 
Family
history
Microalbuminuria(mg/l) Chi- 
square
Degree
of
Freedom 
Significance
<20 20 Total 
Yes 3 16 19  
1.133 1 P>0.05No 9 22 31 
Total 12 38 50 
The observation from the above table shows that there was no 
significant association between microalbuminuria and family history of 
disease (P>0.05).That means both were independent.
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14. Association between total cholesterol and microalbuminuria: 
Table15:Association between total cholesterol and microalbuminuria 
Total
Cholesterol
(mg%)
Microalbuminuria
          (mg/l) 
  Chi- 
square
Degree of
freedom 
Significance
<20 20 Total 
Normal (<200) 10 28   38  
0.466         1    P>0.05  Abnormal (200) 2 10   12 
Total 12 38   50 
There are 12 patients with abnormal total Cholesterol, out of  
which 10 patients (83.33%) had Microalbuminuria and out of 38 patients 
(73.68%) with normal total cholesterol, 28 had microalbuminuria. The 
observation from above table shows that there was no significant 
association between total cholesterol and microalbuminuria (P>0.05) 
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15. Association between microalbuminuria and triglycerides (TGL): 
Table 16: Association between microalbuminuria and triglycerides 
TGL(mg/dl) 
Microalbuminuria
(mg/l)
Chi-
square
Degree of 
freedom 
Significance
<20 20 Total
0.829 1 P>0.05Normal(150) 9 23 32 
Abnormal(>150) 3 15 18 
Total 12 38 50 
There are 32 patients with normal TGL, out of which 23 had 
microalbuminuria and in 18 patients with abnormal TGL, 15 had 
microalbuminuria. The results of the above table shows that there is no 
significant association between TGL and microalbuminuria (P>0.05).    
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16. Association between microalbuminuria and HDL: 
Table 17: Association between microalbuminuria and HDL 
HDL(mg/dl) Microalbuminuria 
         (mg/l) 
Chi-
square
Degree of 
freedom 
Significance
<20 20 Total
 0.084       1    P>0.05 Normal 8 27 35 
Abnormal 4 11 15 
Total 12 38 50 
There are 15 patients with abnormal HDL, out of which 11 had 
microalbuminuria and out of 35 patients with normal HDL, 27 had 
microalbuminuria. The results of the above table shows no statistically 
significant association between microalbuminuria and HDL (P>0.05)  
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17. Association between microalbuminuria and LDL: 
Table 18: Association between microalbuminuria and LDL 
LDL(mg/dl) Microalbuminuria 
(mg/l)
Chi
-square
Degree
of freedom 
Significance
<2
0
2
0
Total
   2.562        1     P>0.05 
Normal 10 22 32 
Abnormal(130) 2 16 18 
Total 12 38 50 
There are 18 patients with abnormal LDL, out of which 16 patients 
had microalbuminuria and out of 32 with normal LDL,22 had 
microalbuminuria. The results of the above table shows no statistically 
significant association between microalbuminuria and LDL (P>0.05). 
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DISCUSSION 
Ischemic heart disease will become a major disease burden in India 
by the year 2015.60 To target preventive strategies, risk stratification of 
the population should be effective. There are many reports emanating 
from the western literature about microalbuminuria as an independent 
risk factor for development of IHD.
This study had 76% male patients compared to 26% female 
patients. This is in accordance with males are more prone for IHD than 
females. 
The mean age of study population was 55.8±10.7 years. The 
median age was 57 years. The mean age of males was 53.8±11.6years 
and the same of females was 60.5±6.7 years. The significant difference of 
mean age between the sexes shows that male are affected by coronary 
heart disease quite earlier than females(Table - 5).All the females were in 
post-menopausal age group, which shows that sex hormones has a 
protective effect as far as cardiovascular system is concerned.
Smoking is present in 66% of the study subjects .Among males 
94.3% were smokers but none of the females were smokers (Table 7).The 
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smokers had been affected by the disease quite earlier than       
the nonsmokers, since the mean age of the smokers was 52.9±11years 
and the mean age of nonsmokers was 61.5± 6.8 years. The difference  
between the mean was statistically  highly significant (P <0.01).This 
indicates that smoking is an important risk factor for IHD.Umesh N khot 
et al62 had found a prevalence of 41.6% in males and 29.5% in females in 
their  study for smoking as a risk factor.
Family history of IHD was present in only 19% of study subjects. 
H. C. Hillege et al had an incidence of 29%.
The mean fasting blood glucose was 100±8.6mg/dl, the mean 
systolic BP was 115.6±9.5 mmHg, the mean diastolic BP- 
74.8±6.5mmHg indicating all patients are non-diabetic non-hypertensive.
The mean Total cholesterol was 178±26.8, mean TGL was 
144.5±51.1, mean HDL was 42.6±3.8, mean LDL was 123±24.8.The 
major dyslipidemia in the study subjects were increased TGL (36%), 
increased LDL (36%) and decreased HDL (30%).
The present study showed that 76% of patients with IHD had 
microalbuminuria which shows a positive association.
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The PREVEND study62 showed that in a multivariate model 
adjusted for established cardiovascular risk factor, microalbuminuria was 
independently associated with infarct pattern (7.1%)(OR-1.61),major 
ischemia (10.6%)(OR-1.43),minor ischemia(15.1%)(OR-1.32).
In the PREVEND study62, 32.8% of patients had microalbuminuria 
and in HOPE study cohort conducted betwen 1994 – 199963, 20.4% had 
microalbuminuria compared to 76% in our study. This was probably 
because the present study had a cohort of IHD patients in whom 
microalbuminuria was estimated whereas the studies mentioned above 
was done on the general population.
The smoking habit was not statistically significantly associated 
with microalbuminuria (P>0.05).
The lipid profile was not statistically significantly associated with 
microalbuminuria (P>0.05).        
L.Gomes MB, Da Cruz et al. showed the incidence of lipid 
abnormality in >45% of diabetic patients. 
Campus VM, Blanchis et al showed the incidence of lipid 
abnormality in essential hypertension as 44 – 48%. In our study the 
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incidence of hyperlipidemia was below 37%.This shows hyperlipidemia 
is more prevalent in diabetic and hypertensive patients with CAD.
The present study showed microalbuminuria can be used as an 
additional cardiovascular risk indicator even in non-diabetic and non- 
hypertensive individual.
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SUMMARY
¾ Male to female ratio was 2.33: 1 
¾ Subjects in the age group 50 – 59 years constituted 42% of the study 
subjects.
¾ The youngest patient in the study was 26 years 
¾ Family history of IHD was present in 38% of study subjects. 
¾ Smoking history was present in 66% of study subjects. All of them are 
males (94.3%). Smokers are affected by disease quite earlier than      
non smokers. 
¾ The abnormal lipid pattern seen was increased triglyceride (36%), 
increased LDL (36%) and decreased HDL (30%)  
¾ Smoking and hyperlipidemia was not significantly associated with 
non-diabetic non-hypertensive coronary artery disease patients. 
¾ Microalbuminuria (20mg/l) was present in 76% of study subjects 
with coronary artery disease. 
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CONCLUSION
¾ Among the 50 non-diabetic non-hypertensive CAD patients, 38 
patients (76%) had microalbuminuria. 
¾ Microalbuminuria is positively associated with the Ischemic heart 
disease in non-diabetic non-hypertensive CAD patients and can be 
regarded as additional risk factor for ischemic heart disease. 
¾ Hence screening for microalbuminuria is a worthwhile public tool for 
cardiac risk stratification and targeting preventive strategies. 
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PROFORMA
Name:           Age:      
Sex:
OP/IP Number:                      Occupation: 
Presenting complaints:                               
Chestpain / breathlessness / palpitation / syncope / others 
Past history: 
Family history: 
Personal history: 
General examination: 
Vital signs 
Examination of cardiovascular system 
Examination of respiratory system 
Abdominal examination 
Examination of Central nervous system 
Investigations:
Urine – Albumin:         Sugar:            Deposits:
Early morning first void microalbumin: 
Fasting blood sugar:         Urea:
Creatinine:
Fasting serum lipid profile:                                    
Total cholesterol:      TGL:               HDL:                 LDL: 
12  lead ECG,  Cardiac enzyme estimation, Echocardiogram. 
S. No Name IP/OPNo Age Sex
Family
H/o
IHD
Smokin
g
SBP
mmHg
DBP
mmHg
FBS
mg%
TC
mg%
TGL
mg%
HDL
mg%
LDL
mg%
Micro
albuminuria
mg/l
1 Prabhakaran 36886 34 M Yes Yes 120 70 110 142 110 39 81 30
2 Samuel 29323 35 M No Yes 110 80 110 249 179 40 185 30
3 Krishnan 34231 72 M Yes Yes 130 80 105 208 154 41 128 16
4 Subramani 20126 53 M Yes Yes 120 60 104 186 102 40 125 68
5 Sivakami 35255 64 F No No 130 70 110 176 141 39 11 7
6 Muthammal 38354 58 F Yes No 120 80 99 240 170 41 184 37
7 Muthukumaraswamy 12252 74 M Yes Yes 130 80 94 161 119 40 97 24
8 Arumugam 45196 67 M Yes Yes 120 80 103 156 116 40 92 30
9 Kandaswamy 25971 56 M No Yes 100 70 107 175 120 44 107 18
10 Rajammal 33155 59 F Yes No 110 80 101 217 100 48 149 27
11 Maharajan 39684 33 M No Yes 110 70 110 202 167 49 120 61
12 Pappa 37904 51 F No No 120 70 109 179 111 52 104 64
13 Sankaran 30325 65 M Yes Yes 130 80 98 184 101 45 120 82
14 Mani 29240 47 M No Yes 110 70 94 178 187 48 92 30
15 Rajaram 16355 61 M No Yes 100 80 100 180 110 48 124 16
16 Sankar 40424 26 M No Yes 100 70 110 160 120 40 120 30
17 Eswaran 13244 58 M Yes Yes 120 70 104 188 114 40 138 70
18 Peer mohamed 23355 50 M Yes Yes 110 80 108 154 114 42 98 29
19 Gandhi 16490 55 M No Yes 130 70 100 110 115 40 120 30
20 Sornathammal 14207 57 F No No 110 80 98 190 441 30 130 28
21 Vembu 37585 69 M Yes No 120 60 104 175 146 45 120 49
22 Chellammal 50064 62 F No No 130 80 110 185 192 46 100 25
23 Lakshmanan 23172 62 M No Yes 100 70 108 180 110 44 194 60
24 Ganapathy 39322 50 F No No 100 80 104 210 164 44 138 24
25 Eruthayamani 49597 69 M Yes No 110 60 100 200 160 44 170 28
26 Pandaram 30345 58 M No Yes 120 80 96 142 110 42 90 15
27 Perumal 17680 40 M No Yes 110 70 102 180 110 42 130 29
28 Sedhu 29196 50 M Yes Yes 120 80 82 114 120 40 94 34
29 Shanmugam 31654 56 M No Yes 110 80 90 142 110 42 90 15
30 Chithra 44433 53 F No No 110 70 112 170 100 45 120 29
31 Abdul kadar 30434 50 M No Yes 110 80 84 204 170 44 132 38
32 Petchiammal 17362 61 F No No 130 80 100 176 141 35 114 18
33 Sankarammal 50847 63 F No No 120 70 99 200 168 43 140 44
34 Sheik abdul kadar 16010 72 M Yes Yes 120 80 98 184 192 44 108 30
35 Muthukrishnan 22052 40 M No Yes 130 80 90 150 14 40 110 18
36 Paul raj 13068 54 M Yes  yes 110 80 80 160 120 44 108 29
37 Damodaran 31083 42 M No Yes 120 70 88 180 134 43 127 61
38 Ramachandran 25995 48 M No Yes 100 70 98 210 165 42 170 19
39 Srinivasan 22180 54 M Yes Yes 110 80 100 210 174 4 134 30
40 Sankarapandian 14734 40 M No Yes 120 70 104 175 140 38 120 17
41 Alagammal 46006 62 F No No 110 80 90 185 192 44 110 43
42 Chelladurai 27895 42 M No Yes 120 80 80 180 153 40 130 35
43 soosaimuthu 13704 60 M No Yes 130 70 88 210 174 43 134 30
44 Ramiah 32672 56 M Yes Yes 120 60 90 154 140 43 136 28
45 Petchiammal 17669 71 F Yes No 110 80 100 178 110 50 110 14
46 Seenivasan 40455 58 M No Yes 100 80 99 160 120 42 110 44
47 Muthammal 50487 75 F No No 120 80 102 175 146 40 112 60
48 Maagani 31661 62 F Yes No 110 80 112 158 164 39 134 15
49 Saraswathy 45854 60 F No No 110 70 104 170 150 46 108 20
50 Arumugam 16902 57 M No Yes 120 80 114 170 134 45 130 58
MASTER CHART
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      KEY TO MASTER CHART 
I P oInpatients
O P oOut patients 
H/0 oHistory
SBP oSystolic blood pressure 
DBP oDiastolic blood pressure 
FBS oFasting blood sugar 
TC oTotal cholesterol 
TGL oTriglycerides
HDL oHigh density lipoprotein 
LDL   oLow density lipoprotein 
IHD oIschemic heart disease 
S.No oSerial number 
